2358-54-5

Usage

Uses

Used in Adhesives Industry:
2-(2,2,2-TRIFLUOROETHOXY)ETHANOL is used as a solvent for adhesives, enhancing their performance and ensuring strong bonding capabilities. Its unique properties contribute to the adhesive's effectiveness in various applications.
Used in Inks Industry:
In the inks industry, 2-(2,2,2-TRIFLUOROETHOXY)ETHANOL serves as a solvent, improving the flow and consistency of inks, which is crucial for high-quality printing and graphic arts.
Used in Coatings Industry:
2-(2,2,2-TRIFLUOROETHOXY)ETHANOL is utilized as a solvent in coatings, providing a smooth application and enhancing the durability and finish of the final product.
Used as a Chemical Intermediate:
Beyond its direct applications, 2-(2,2,2-TRIFLUOROETHOXY)ETHANOL also functions as a chemical intermediate, playing a pivotal role in the synthesis of other compounds, thereby expanding its utility across the chemical industry.

InChI:InChI=1/C4H7F3O2/c5-4(6,7)3-9-2-1-8/h8H,1-3H2

Upstream product

• 75-21-8 oxirane 
• 75-89-8 2,2,2-trifluoroethanol 
• 96-49-1 [1,3]-dioxolan-2-one 
• 311-28-4 tetra-(n-butyl)ammonium iodide 
• 1098411-87-0 2-tetrahydropyran-2-yloxyethyl 2,2,2-trifluoroethyl ether 
• 252947-89-0 tert-butyl 2-(2,2,2-trifluoroethoxy)acetate 

Downstream Products

• 1537-70-8 5-chloro-1,1,1-trifluoro-3-oxapentane 
• 252947-90-3 2-(2, 2, 2-trifluoroethoxy)ethyl 4-methylbenzenesulfonate 
• 1255707-52-8 methyl 4-bromo-3-(2-(2,2,2-trifluoroethoxy)ethoxy)benzoate 

Relevant academic research and scientific papers

Synthesis of new fluorine-containing room temperature ionic liquids and their physical and electrochemical properties

An improved synthesis of fluorine-containing room temperature ionic liquids (FRTILs) is described. Twelve FRTILs are synthesized, in which the fluorinated cations based on N-methyl pyrrolidinium (MPy), 1-methly imidazolium (MIm) and diethylsulfide (DES) a

HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR

Disclosed in the present invention is a new 11-oxo-7,11-dihydro-6h-benzo-[f]pyrido[1,2-d][1,4]azepine oxepin-10-carboxylic acid derivative serving as a hepatitis B virus surface antigen inhibitor. Specifically disclosed are a compound represented by formula (V) or a pharmaceutically acceptable salt thereof, and applications of the compound represented by formula (V) or the pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof in the treatment of viral hepatitis B.

Polymeric 19F MRI Contrast Agents Prepared by Ring-Opening Metathesis Polymerization/Dihydroxylation

The capability of ring-opening metathesis polymerization (ROMP) to efficiently incorporate bulky monomers and conserve olefin bonds during polymerization was exploited to design water-soluble fluoropolymers, which were evaluated as potential quantitative 19F magnetic resonance imaging (MRI) contrast agents. The fluoromonomeric units comprised 3, 6, 9, or 18 magnetically equivalent fluorine atoms. Aqueous solubility was achieved through dihydroxylation of the partially unsaturated polymeric backbone and by tetraethylene glycol (TEG)-based linker incorporation, ammonium quaternization, or copolymerization.

Synthesis and physical properties of new fluoroether sulfones

Eight new strategically designed fluoroether sulfone solvents have been synthesized through different synthetic pathways for potential applications in lithium-sulfur battery electrolytes. The structures of these compounds have been confirmed by 1H-NMR, 13C-NMR and elemental analysis. Several 1,2-dimethoxyethane (DME)-based electrolyte formulations have been prepared with these solvents to derive an electrolyte with good ionic conductivity (>5 mS cm?1 at 25 ℃). The viscosity of these new additives has also been determined as it is directly related to the ionic conductivity. Three of these solvents that contain a trifluoromethyl group displayed acceptable ionic conductivity.

Glucopyranosyl derivative and application thereof in medicines

The invention relates to a glucopyranosyl derivative used as a sodium-dependent glucose transporter (SGLT) inhibitor, a medicinal composition containing the derivative, and an application of the derivative and the medicinal composition in medicines, and especially relates to the glucopyranosyl derivative represented by formula (I) or a pharmaceutically acceptable salt or all stereoisomers thereof, or the medicinal composition containing the derivative, and a use of the derivative and the medicinal composition in the preparation of medicines for treating diabetes and diabetes related diseases.

HYDRO-FLUOROCOMPOUNDS

The invention pertains to certain hydro-fluorocompounds of the following formula (I): RfO-RH-O-(CH2)m-[CF(X)]n-COOXa wherein: - Xa is H, a monovalent metal (preferably an alkaline metal) or an ammonium group of formula -N(R'n)4, wherein each of R'n, equal to or different from each other, independently represents a hydrogen atom or a C1-6 hydrocarbon group (preferably an alkyl group); - Rf is a C1-C6 (per)fluoroalkyl optionally comprising one or more catenary oxygen atoms, preferably Rf is a group of formula R'f-CH2-, wherein R'f is a C1-C5 perfluorinated group, possibly comprising one or more ethereal oxygens, preferably a C1-C3 perfluorinated group, possibly comprising one or more ethereal oxygens; - RH is a fluorine-free hydrocarbon group optionally comprising one or more catenary oxygen atoms; - X is F or CF3, preferably X is F; - m is 0 or 1; - n is 1 to 3, to a process for the manufacture of said hydro-fluorocompounds, to a method of making fluoropolymers in the presence of said hydro-fluorocompounds, and to fluoropolymer dispersions comprising said hydro-fluorocompound.

BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION

This invention relates to compounds of formula (I).

Benzopyran or thiobenzopyran derivatives

The present invention provides novel benzopyran compounds, pharmaceutically acceptable salts thereof and stereoisomers thereof where the benzopyran compounds of the invention are compounds according to Formula I: The present invention further provides pharmaceutical compositions which possess anti-estrogenic activity and comprise at least one benzopyran compound of the invention and a method of treating breast cancer by administration of an effective amount of a benzopyran compound provided by the present invention.

Benzimidazole derivatives

A benzimidazole derivative of formula (1): (wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same. The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.